Bullish Healthcare Stocks
Analysts Highlight Strong Growth Potential and Bullish Sentiment Across Major Healthcare Stocks
Anonymous
Key Points
1
Abivax analyst Sam Slutsky was described as a top-100 analyst, with a reported average return of 47.9% and a 53.2% success rate. Goldman Sachs had also initiated coverage with a Buy rating and a $155 price target.
2
Eli Lilly analyst Mohit Bansal was identified as a five-star analyst, with a reported average return of 11.6% and a 62.3% success rate; Berenberg Bank had separately upgraded Lilly to Buy with a $1,400 price target.
3
The Creative Medical Technology–argenx comparison put their volatility in stark contrast: Creative Medical Technology had a beta of 2.04, or 104% more volatility than the S&P 500, while argenx had a beta of 0.47, or 53% less volatility than the index.
4
In the Pharming Group–Rhythm Pharmaceuticals comparison, Pharming had no reported institutional ownership, while insiders held 2.1% of its shares; Rhythm had 5.9% insider ownership.
5
The Pharming–Rhythm comparison also reported an extreme difference in beta: Pharming’s beta was 0.01, indicating 99% lower volatility than the S&P 500, versus Rhythm’s beta of 1.97, indicating 97% higher volatility than the index.
Healthcare analysts are backing several biotech and pharma stocks with bullish outlooks and strong ratings. TipRanks reports that Abivax and Eli Lilly both earned Buy ratings, with price targets of $168 and $1,330 respectively, while broader analyst consensus rated both as Strong Buy. Company-to-company comparisons reveal sharper contrasts, with argenx favored over Creative Medical Technology and Pharming Group outperforming Rhythm Pharmaceuticals across most measured factors.
Top Analysts Back Abivax and Eli Lilly
Sam Slutsky, ranked among the top 100 analysts, maintains a Buy on Abivax with a $168 price target. TipRanks notes Slutsky has delivered an average return of 47.9% with a 53.2% success rate. Goldman Sachs separately initiated coverage on Abivax with a Buy rating and $155 target, reinforcing bullish sentiment.
Eli Lilly drew backing from five-star analyst Mohit Bansal, who shows a 62.3% success rate and 11.6% average return. TipRanks also reports Berenberg Bank upgraded Lilly to Buy with a $1,400 price target, giving the stock multiple bullish calls at varied target levels above current prices.
Volatility Gap Widens Between argenx and Creative Medical
argenx emerged as the stronger choice in direct head-to-head comparison, winning 13 of 15 measured factors despite Creative Medical Technology's cheaper valuation. TipRanks highlights a stark risk difference: Creative Medical carried a beta of 2.04—meaning 104% more volatility than the S&P 500—while argenx posted a beta of 0.47, representing 53% less volatility than the broader market.
argenx's advantages extended across multiple metrics. The company showed stronger revenue, higher earnings, greater institutional ownership, and lower price swings. For risk-averse investors, argenx's calm trading pattern contrasted sharply with Creative Medical's wild price movements.
Pharming Crushes Rhythm on Stability and Upside
Pharming Group beat Rhythm Pharmaceuticals on nine of 14 comparison metrics, driven largely by implied upside and dramatically lower volatility. TipRanks reports Pharming's beta stood at 0.01—nearly flat, with 99% less volatility than the S&P 500—while Rhythm's beta hit 1.97, indicating 97% higher volatility than the index. This extreme gap made Pharming appealing to conservative investors.
Ownership structures differed sharply between the two. Pharming reported zero institutional ownership with insiders holding just 2.1% of shares, while Rhythm showed 5.9% insider ownership. Analysts weighted Pharming's substantially higher price-target upside as the decisive factor despite its thinner institutional backing.
Analyst Ratings Hinge on Valuation and Risk Mix
These ratings and comparisons reflect analyst opinion based on differing valuation methods, profitability metrics, ownership concentration, and volatility levels. TipRanks emphasizes that no single measure determines the winner—some analysts prioritize upside, others emphasize downside protection. Past analyst success rates do not guarantee future returns.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
15
Articles
2
Reach
17
A
AnonymousAuthor
